Cited by 128Antifungal resistance and susceptibilityAntibiotic Use and ResistanceOcular Infections and Treatments

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study

Open access

Zilberberg, Marya D, Kollef, Marin H, Arnold, Heather, Labelle, Andrew, Micek, Scott T, Kothari, Smita, Shorr, Andrew F·2010·BMC Infectious Diseases

DOI 10.1186/1471-2334-10-150PMC PMC2890008

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Candida represents the most common cause of invasive fungal disease, and candidal blood stream infections (CBSI) are prevalent in the ICU. Inappropriate antifungal therapy (IAT) is known to increase a patient's risk for death. We hypothesized that in an ICU cohort it would also adversely affect resource utilization. METHODS: We retrospectively identified all patients with candidemia on or before hospital day 14 and requiring an ICU stay at Barnes-Jewish Hospital between 2004 and 2007. Hospital length of stay following culture-proven onset of CBSI (post-CBSI HLOS) was primary and hospital costs secondary endpoints. IAT was defined as treatment delay of > or =24 hours from candidemia onset or inadequate dose of antifungal agent active against the pathogen. We developed generalized linear models (GLM) to assess independent impact of inappropriate therapy on LOS and costs. RESULTS: Ninety patients met inclusion criteria. IAT was frequent (88.9%). In the IAT group antifungal delay > or =24 hours occurred in 95.0% and inappropriate dosage in 26.3%. Unadjusted hospital mortality was greater among IAT (28.8%) than non-IAT (0%) patients, p = 0.059. Both crude post-CBSI HLOS (18.4 +/- 17.0 vs. 10.7 +/- 9.4, p = 0.062) and total costs ($66,584 +/- $49,120 vs. $33,526 +/- $27,244, p = 0.006) were higher in IAT than in non-IAT. In GLMs adjusting for confounders IAT-attributable excess post-CBSI HLOS was 7.7 days (95% CI 0.6-13.5) and attributable total costs were $13,398 (95% CI $1,060-$26,736). CONCLUSIONS: IAT of CBSI, such as delays and incorrect dosing, occurs commonly. In addition to its adverse impact on clinical outcomes, IAT results in substantial prolongation of hospital LOS and increase in hospital costs. Efforts to enhance rates of appropriate therapy for candidemia may improve resource use.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1186/1471-2334-10-150

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“is the most frequent cause of invasive fungal disease in hospitalized patients [1].”
Background
Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007
Hidron, A. I., Edwards, J. R., Patel, J., Horan, T. C., Sievert, D. M., Pollock, D. A., Fridkin, S. K., & National Healthcare Safety Network Team and Participating National Healthcare Safety Network Facilities (2008) · Infection Control & Hospital Epidemiology · doi:10.1086/591861 · Cited by 3,724
Delaying the Empiric Treatment of Candida Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital Mortality
Morrell, M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3640-3645.2005 · Cited by 1,286
Self-citation
Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study.
Garey, K. W., Rege, M., Pai, M. P., Mingo, D. E., Suda, K. J., Turpin, R. S., & Bearden, D. T. (2006) · Clinical Infectious Diseases · doi:10.1086/504810 · Cited by 1,171
The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis
Zaoutis, T. E., Argon, J., Chu, J., Berlin, J. A., Walsh, T. J., & Feudtner, C. (2005) · Clinical Infectious Diseases · doi:10.1086/496922 · Cited by 784
The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance
Hong Nguyen, M., Peacock, J. E., Morris, A. J., Tanner, D. C., Nguyen, M. L., Snydman, D. R., Wagener, M. M., Rinaldi, M. G., & Yu, V. L. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(95)00010-0 · Cited by 758
A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization*
León, C., Ruiz-Santana, S., Saavedra, P., Almirante, B., Nolla-Salas, J., Álvarez-Lerma, F., Garnacho-Montero, J., & León, M. Á. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000202208.37364.7d · Cited by 659
Before–after study of a standardized hospital order set for the management of septic shock*
Micek, S. T., Roubinian, N. H., Heuring, T., Bode, M., Williams, J. A. S., Harrison, C., Murphy, T., Prentice, D., Ruoff, B. E., & Kollef, M. H. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000241151.25426.d7 · Cited by 373
Self-citation
Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting
Ostrosky-Zeichner, L., Sable, C., Sobel, J., Alexander, B. D., Donowitz, G., Kan, V., Kauffman, C. A., Kett, D., Larsen, R. A., Morrison, V., et al. (2007) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-007-0270-z · Cited by 369
Bench-to-bedside review: Candida infections in the intensive care unit
Méan, M., Marchetti, O., & Calandra, T. (2008) · Critical Care · doi:10.1186/cc6212 · Cited by 217

Show all 19 references

Sorted by citations

Septic shock attributed to Candida infection: Importance of empiric therapy and source control.
Kollef, M., Micek, S., Hampton, N., Doherty, J. A., & Kumar, A. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis305 · Cited by 477
Self-citation
Molecular and Nonmolecular Diagnostic Methods for Invasive Fungal Infections
Arvanitis, M., Anagnostou, T., Fuchs, B. B., Caliendo, A. M., & Mylonakis, E. E. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00091-13 · Cited by 367
Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002–2010)
The French Mycosis Study Group, Lortholary, O., Renaudat, C., Sitbon, K., Madec, Y., Denoeud‐Ndam, L., Wolff, M., Fontanet, A. L., Bretagne, S., & Dromer, F. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3408-3 · Cited by 310
Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in intensive care unit (ICU) and non-ICU settings in the SENTRY antimicrobial surveillance program (2008–2009)
Pfaller, M. A., Messer, S. A., Moet, G. J., Jones, R. N., & Castanheira, M. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.02.016 · Cited by 274
Defining breakthrough invasive fungal infection–Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology
Cornely, O. A., Hoenigl, M., Lass‐Flörl, C., Chen, S. C. ‐., Kontoyiannis, D. P., Morrissey, C. O., & Thompson, G. R. (2019) · Mycoses · doi:10.1111/myc.12960 · Cited by 229
Risk Factors and Outcomes of Candidemia Caused by Biofilm-Forming Isolates in a Tertiary Care Hospital
Tumbarello, M., Fiori, B., Trecarichi, E. M., Posteraro, P., Losito, A. R., Luca, A. D., Sanguinetti, M., Fadda, G., Cauda, R., & Posteraro, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033705 · Cited by 201
Breakthrough invasive fungal infections: Who is at risk?
Jenks, J. D., Cornely, O. A., Chen, S. C. ‐., Thompson, G. R., & Hoenigl, M. (2020) · Mycoses · doi:10.1111/myc.13148 · Cited by 191
Invasive Mycoses: Diagnostic Challenges
Ostrosky‐Zeichner, L. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.10.008 · Cited by 178
Nosocomial Candidiasis: Antifungal Stewardship and the Importance of Rapid Diagnosis
Pfaller, M. A., & Castanheira, M. (2015) · Medical Mycology · doi:10.1093/mmy/myv076 · Cited by 166
T2MR and T2Candida: novel technology for the rapid diagnosis of candidemia and invasive candidiasis
Pfaller, M. A., Wolk, D. M., & Lowery, T. J. (2015) · Future Microbiology · doi:10.2217/fmb.15.111 · Cited by 157
Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study
Sinnollareddy, M., Roberts, J. A., Lipman, J., Akova, M., Bassetti, M., Waele, J. J. D., Kaukonen, K.-M., Koulenti, D., Martin, C., Montravers, P., et al. (2015) · Critical Care · doi:10.1186/s13054-015-0758-3 · Cited by 147
Sepsis: the LightCycler SeptiFast Test MGRADE®, SepsiTest™ and IRIDICA BAC BSI assay for rapidly identifying bloodstream bacteria and fungi – a systematic review and economic evaluation
Stevenson, M., Pandor, A., James, M. M., Rafia, R., Uttley, L., Stevens, J., Sanderson, J., Wong, R., Perkins, G. D., McMullan, R., et al. (2016) · Health Technology Assessment · doi:10.3310/hta20460 · Cited by 141
The risk and clinical outcome of candidemia depending on underlying malignancy
The French Mycoses Study Group, Lortholary, O., Renaudat, C., Sitbon, K., Desnos‐Ollivier, M., Bretagne, S., & Dromer, F. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4743-y · Cited by 131
The case for antifungal stewardship
Ananda-Rajah, M. R., Slavin, M. A., & Thursky, K. (2011) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32834e0680 · Cited by 128
Evaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently needed
Valerio, M., Rodríguez-González, C. G., Munoz, P., Caliz, B., Sanjurjo‐Sáez, M., Bouza, E., on behalf of the COMIC Study Group (Collaborative Group on Mycoses), Anaya, F., Bañares, R., Bouza, E., et al. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku053 · Cited by 127
Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes
Grim, S. A., Berger, K., Teng, C. B., Gupta, S., Layden, J. E., Janda, W. M., & Clark, N. M. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr511 · Cited by 119
Adherence to recommendations for the use of antifungal agents in a tertiary care hospital
Nivoix, Y., Launoy, A., Lutun, P., Moulin, J., Pang, K.-A. P., Fornecker, L., Wolf, M., Levêque, D., Letscher‐Bru, V., Beretz, L., et al. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks256 · Cited by 83
A Prospective Surveillance Study of Candidaemia: Epidemiology, Risk Factors, Antifungal Treatment and Outcome in Hospitalized Patients
Rajendran, R., Sherry, L., Deshpande, A., Johnson, E. M., Hanson, M., Williams, C., Munro, C. A., Jones, B., & Ramage, G. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00915 · Cited by 82
A multiplex nested PCR for the detection and identification of Candida species in blood samples of critically ill paediatric patients
Taira, C. L., Okay, T. S., Delgado, A. F., Ceccon, M. E. J. R., de Almeida, M. T. G., & Negro, G. M. B. D. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-406 · Cited by 68
Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting
Lepak, A., & Andes, D. (2011) · Critical Care Clinics · doi:10.1016/j.ccc.2010.11.001 · Cited by 62
Yeast identification in routine clinical microbiology laboratory and its clinical relevance
Agarwal, S. K., Manchanda, V., Verma, N., & Bhalla, P. (2011) · Indian Journal of Medical Microbiology · doi:10.4103/0255-0857.81794 · Cited by 62
Wild-Type MIC Distributions and Epidemiological Cutoff Values for Posaconazole and Voriconazole and Candida spp. as Determined by 24-Hour CLSI Broth Microdilution
Pfaller, M. A., Boyken, L. B., Hollis, R. J., Kroeger, J. S., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02161-10 · Cited by 61
Advances in Candida detection platforms for clinical and point-of-care applications
Safavieh, M., Coarsey, C., Esiobu, N., Memic, A., Vyas, J. M., Shafiee, H., & Asghar, W. (2017) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2016.1167667 · Cited by 57
Candida glabrata : an emerging pathogen in Brazilian tertiary care hospitals
Colombo, A. L., Garnica, M. M., Camargo, L. F. A., da Cunha, C. A., Bandeira, A. C., Borghi, D. P., Campos, T., Senna, A. L., Didier, M. E. V., Dias, V. C., et al. (2012) · Medical Mycology · doi:10.3109/13693786.2012.698024 · Cited by 57
Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: A systematic review.
Sinnollareddy, M., Peake, S. L., Roberts, M. S., Lipman, J., & Roberts, J. A. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.07.013 · Cited by 56
Mortality and risk factor analysis for Candida blood stream infection: A multicenter study
Kato, H., Yoshimura, Y., Suido, Y., Shimizu, H., Ide, K., Sugiyama, Y., Matsuno, K., & Nakajima, H. (2019) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2019.01.002 · Cited by 59
How much European prescribing physicians know about invasive fungal infections management?
Valerio, M., Vena, A., Bouza, E., Reiter, N., Viale, P., Hochreiter, M., Giannella, M., Muñóz, P., & on behalf the COMIC study group (Collaborative group on Mycosis) (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-0809-z · Cited by 50
Prevalence of, and risk factors for, hematogenous fungal endophthalmitis in patients with Candida bloodstream infection
Kato, H., Yoshimura, Y., Suido, Y., Ide, K., Sugiyama, Y., Matsuno, K., & Nakajima, H. (2018) · Infection · doi:10.1007/s15010-018-1163-z · Cited by 51
Choosing the Right Antifungal Agent in ICU Patients
Chatelon, J., Cortegiani, A., Hammad, E., Cassir, N., & Léone, M. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01115-0 · Cited by 52
Mortality in patients with early- or late-onset candidaemia
Rosa, F. G. D., Trecarichi, E. M., Montrucchio, C., Losito, A. R., Raviolo, S., Posteraro, B., Corcione, S., Giambenedetto, S. D., Fossati, L., Sanguinetti, M., et al. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks480 · Cited by 50
The Effect of Inadequate Initial Empiric Antimicrobial Treatment on Mortality in Critically Ill Patients with Bloodstream Infections: A Multi-Centre Retrospective Cohort Study
Savage, R., Fowler, R., Rishu, A. H., Bagshaw, S. M., Cook, D., Dodek, P., Hall, R., Kumar, A., Lamontagne, F., Lauzier, F., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154944 · Cited by 49
Antifungal Susceptibility Patterns,In VitroProduction of Virulence Factors, and Evaluation of Diagnostic Modalities for the Speciation of PathogenicCandidafrom Blood Stream Infections and Vulvovaginal Candidiasis
Tellapragada, C., Eshwara, V. K., Johar, R., Shaw, T., Malik, N., Bhat, P. V., Kamath, A., & Mukhopadhyay, C. (2014) · Journal of Pathogens · doi:10.1155/2014/142864 · Cited by 47
The epidemiology of bloodstream infection contributing to mortality: the difference between community-acquired, healthcare-associated, and hospital-acquired infections
Mun, S. J., Kim, S., Kim, H., Moon, C., & Wi, Y. M. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07267-9 · Cited by 47
1,3‐ß‐D‐glucan concentrations in blood products predict false positive post‐transfusion results
Liss, B., Cornely, O. A., Hoffmann, D., Dimitriou, V., & Wisplinghoff, H. (2015) · Mycoses · doi:10.1111/myc.12432 · Cited by 42
An institutional perspective on the impact of recent antibiotic exposure on length of stay and hospital costs for patients with gram-negative sepsis
Micek, S. T., Johnson, M. T., Reichley, R. M., & Kollef, M. H. (2012) · BMC Infectious Diseases · doi:10.1186/1471-2334-12-56 · Cited by 41
Self-citation
Epidemiology of Culture-confirmed Candidemia Among Hospitalized Children in South Africa, 2012–2017
Shuping, L., Mpembe, R. S., Mhlanga, M., Naicker, S. D., Maphanga, T. G., Tsotetsi, E., Wadula, J., Velaphi, S., Nakwa, F. L., Chibabhai, V., et al. (2021) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003151 · Cited by 43
Clinical Practice Patterns in Hospitalized Patients at Risk for Invasive Candidiasis
Aitken, S. L., Beyda, N. D., Shah, D. N., Palmer, H. R., Lasco, T. M., Koo, H. L., & Garey, K. W. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014529928 · Cited by 38
Hospital use of systemic antifungal drugs: a multi-center surveillance update from Germany
Gross, B. N., Steib–Bauert, M., Kern, W. V., Knoth, H., Borde, J., Krebs, S., Hug, M. J., Rothe, U., Maier, L., & de With, K. (2015) · Infection · doi:10.1007/s15010-015-0742-5 · Cited by 35
Cost-Effectiveness Analysis of Multiplex PCR with Magnetic Resonance Detection versus Empiric or Blood Culture-Directed Therapy for Management of Suspected Candidemia
Walker, B. S., Powers‐Fletcher, M. V., Schmidt, R. L., & Hanson, K. E. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.02971-15 · Cited by 37
Real-Time Microscopic Observation of Candida Biofilm Development and Effects Due to Micafungin and Fluconazole
Kaneko, Y., Miyagawa, S., Takeda, O., Hakariya, M., Matsumoto, S., Ohno, H., & Miyazaki, Y. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02290-12 · Cited by 36
Impact of First-Line Antifungal Agents on the Outcomes and Costs of Candidemia
Ha, Y. E., Peck, K. R., Joo, E., Kim, S., Jung, S., Chang, H., Park, K. H., & Han, S. H. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06258-11 · Cited by 36
Optimization of Fluconazole Dosing for the Prevention and Treatment of Invasive Candidiasis Based on the Pharmacokinetics of Fluconazole in Critically Ill Patients
Boonstra, J. M., Märtson, A., Sandaradura, I., Kosterink, J. G. W., van der Werf, T. S., Marriott, D. J. E., Zijlstra, J. G., Touw, D. J., & Alffenaar, J. C. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01554-20 · Cited by 36
Validation of 24-Hour Posaconazole and Voriconazole MIC Readings versus the CLSI 48-Hour Broth Microdilution Reference Method: Application of Epidemiological Cutoff Values to Results from a Global Candida Antifungal Surveillance Program
Pfaller, M. A., Boyken, L. B., Hollis, R. J., Kroeger, J. S., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02437-10 · Cited by 34
Candidemia in the intensive care unit: analysis of direct treatment costs and clinical outcome in patients treated with echinocandins or fluconazole
Heimann, S. M., Cornely, O. A., Wisplinghoff, H., Kochanek, M., Stippel, D. L., Padosch, S. A., Langebartels, G., Reuter, H., Reiner, M., Vierzig, A., et al. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-014-2230-8 · Cited by 36
Candidemia in non-ICU surgical wards: Comparison with medical wards
Vena, A., Bouza, E., Valerio, M., Padilla, B., Paño‐Pardo, J. R., Fernández‐Ruiz, M., Martín, A. D., Salavert, M., Mularoni, A., Puig‐Asensio, M., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185339 · Cited by 32
Mortality and risk factor analysis for Candida blood stream infection: A three-year retrospective study
Müderris, T., Kaya, S., Örmen, B., Gökmen, A. A., Akpınar, C. V., & Gül, S. (2020) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2020.101008 · Cited by 31
Serotypes, antibiotic resistance, and molecular characterization of non-typhoidal salmonella isolated from diarrheic patients in Guangxi Zhuang Autonomous Region, China, 2014–2017
Zeng, X., Lv, S., Qu, C., Lan, L., Tan, D., Li, X., & Bai, L. (2020) · Food Control · doi:10.1016/j.foodcont.2020.107478 · Cited by 29
Implementation of Pharmacist-Driven Antifungal Stewardship Program in a Tertiary Care Hospital
Kara, E., Metan, G., Bayraktar‐Ekincioglu, A., Gülmez, D., Arıkan-Akdağlı, S., Demirkazık, F., Akova, M., Ünal, S., & Uzun, Ö. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00629-21 · Cited by 29
Antimicrobial stewardship without infectious disease physician for patients with candidemia: A before and after study
Murakami, M., Komatsu, H., Sugiyama, M., Ichikawa, Y., Ide, K., Tsuchiya, R., Kunieda, K., Magishi, A., Akiyama, G., 三浦, 文., et al. (2018) · Journal of General and Family Medicine · doi:10.1002/jgf2.159 · Cited by 28
Antifungal therapy in European hospitals: data from the ESAC point-prevalence surveys 2008 and 2009
Zarb, P., Amadéo, B., Muller, A., Drapier, N., Vankerckhoven, V., Davey, P. G., & Goossens, H. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2012.03973.x · Cited by 28
Echinocandins in the treatment of candidaemia and invasive candidiasis: clinical and economic perspectives
Neoh, C. F., Slavin, M. A., Chen, S. C. ‐., Stewart, K., & Kong, D. C. M. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.08.010 · Cited by 28
Clinical characteristics and risk factors for complications of candidaemia in adults: Focus on endophthalmitis, endocarditis, and osteoarticular infections
Shin, S. U., Yu, Y. H., Kim, S. S., Oh, T. H., Kim, S. E., Kim, U. J., Kang, S., Jang, H., Park, K., & Jung, S. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.01.049 · Cited by 28
Candidaemia Observed at a University Hospital in Milan (Northern Italy) and Review of Published Studies from 2010 to 2014
Milazzo, L., Peri, A. M., Mazzali, C., Grande, R., Cazzani, C., Ricaboni, D., Castelli, A., Raimondi, F., Magni, C. F., Galli, M., et al. (2014) · Mycopathologia · doi:10.1007/s11046-014-9786-9 · Cited by 26
The Differences in the Epidemiology and Predictors of Death between Candidemia Acquired in Intensive Care Units and Other Hospital Settings
Li, C., Wang, H., Yin, M., Han, H., Yue, J.-F., Zhang, F., Shan, T., Guo, H., & Wu, D. (2015) · Internal Medicine · doi:10.2169/internalmedicine.54.3744 · Cited by 26
Epidemiology, practice patterns, and prognostic factors for candidemia; and characteristics of fourteen patients with breakthrough Candida bloodstream infections: a single tertiary hospital experience in Japan
Hirano, R., Sakamoto, Y., Kitazawa, J., Yamamoto, S., & Kayaba, H. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s156633 · Cited by 24
Invasive Candidiasis in the Intensive Care Unit: Where Are We Now?
Vázquez, J. A., Whitaker, L., & Zubovskaia, A. (2025) · Journal of Fungi · doi:10.3390/jof11040258 · Cited by 26
Pharmacokinetic evaluation of fluconazole in critically ill patients
Sinnollareddy, M., Peake, S., Roberts, M. S., Playford, E. G., Lipman, J., & Roberts, J. A. (2011) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.615309 · Cited by 22
Identifying Critically Ill Patients at Risk for Inappropriate Antibiotic Therapy
Micek, S. T., Heard, K. M., Gowan, M., & Kollef, M. H. (2014) · Critical Care Medicine · doi:10.1097/ccm.0000000000000337 · Cited by 21
Self-citation
Candidemia Risk Prediction (CanDETEC) Model for Patients With Malignancy: Model Development and Validation in a Single-Center Retrospective Study
Yoo, J., Kim, S., Hur, S., Ha, J., Huh, K., & Cha, W. C. (2021) · JMIR Medical Informatics · doi:10.2196/24651 · Cited by 20
Speciation of Candida using chromogenic and cornmeal agar with determination of fluconazole sensitivity
Golia, S., Reddy., K. M., Karjigi, K. S., & Hittinahalli, V. (2013) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 19
Current recommendations and importance of antifungal stewardship for the management of invasive candidiasis
Miyazaki, T., & Kohno, S. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.1058157 · Cited by 18
Multicenter Evaluation of Candida QuickFISH BC for Identification of Candida Species Directly from Blood Culture Bottles
Abdelhamed, A. M., Zhang, S. X., Watkins, T., Morgan, M. A., Wu, F., Buckner, R. J., Fuller, D., Davis, T. E., Salimnia, H., Fairfax, M. R., et al. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.00549-15 · Cited by 18
Current fluconazole treatment regimens result in under-dosing of critically ill adults during early therapy
Sandaradura, I., Marriott, D. J. E., Day, R. O., Norris, R. L. G., Pang, E., STOCKER, S. L., & Reuter, S. E. (2021) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-021-04201-w · Cited by 18
Hacia el diagnóstico temprano de la candidiasis invasora en el paciente crítico
Pemán, J., & Zaragoza, R. (2012) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2012.03.002 · Cited by 16
Changes in the utilization patterns of antifungal agents, medical cost and clinical outcomes of candidemia from the health-care benefit expansion to include newer antifungal agents
Choi, H., Kim, J. H., Seong, H., Lee, W. J., Jeong, W., Ahn, J. Y., Jeong, S. J., Ku, N. S., Yeom, J., Kim, Y. K., et al. (2019) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2019.03.039 · Cited by 15
Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals
Heimann, S. M., Penack, O., Heinz, W., Rachow, T., Egerer, G., Kessel, J. M., Classen, A. Y., & Vehreschild, J. J. (2019) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2019.04.006 · Cited by 16
Azole antifungals and inter-individual differences in drug metabolism: the role of pharmacogenomics and precision medicine
Biswas, M., John, S., Jinda, P., & Sukasem, C. (2023) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2023.2203860 · Cited by 16
Epidemiology, clinical characteristics, and risk factors for mortality of early- and late-onset invasive candidiasis in intensive care units in China
Yang, Y., Guo, F., Kang, Y., Zang, B., Cui, W., Qin, B., Qin, Y.-Z., Fang, Q., Qin, T., Jiang, D., et al. (2017) · Medicine · doi:10.1097/md.0000000000007830 · Cited by 15
How can we optimise antifungal use in a solid organ transplant centre? Local epidemiology and antifungal stewardship implementation: A single‐centre study
Mularoni, A., Adamoli, L., Polidori, P., Ragonese, B., Gioè, S. M., Pietrosi, A., Tuzzolino, F., Guadagnino, G., Monaco, F., Grossi, P., et al. (2020) · Mycoses · doi:10.1111/myc.13098 · Cited by 15
Relationship of fluconazole prophylaxis with fungal microbiology in hospitalized intra-abdominal surgery patients: a descriptive cohort study
Zilberberg, M. D., Yu, H.-T., Chaudhari, P., Emons, M. F., Khandelwal, N., & Shorr, A. F. (2014) · Critical Care · doi:10.1186/s13054-014-0590-1 · Cited by 15
Self-citation
Validation of 24-Hour Flucytosine MIC Determination by Comparison with 48-Hour Determination by the Clinical and Laboratory Standards Institute M27-A3 Broth Microdilution Reference Method
Lockhart, S. R., Bolden, C. B., Iqbal, N. J., & Kuykendall, R. J. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.05479-11 · Cited by 15
An Observational Study on Early Empiric versus Culture-Directed Antifungal Therapy in Critically Ill with Intra-Abdominal Sepsis
Lee, W., Liew, Y., Chlebicki, M. P., Ong, S. G. K., Lee, P., & Kwa, A. L. (2014) · Critical Care Research and Practice · doi:10.1155/2014/479413 · Cited by 12
Management of Intra-Abdominal Candidiasis in Intensive Care Setting: A Narrative Review
Pais, M. M., Zaragoza, R., Martín‐Loeches, I., Gómez-Bertomeu, F., & Rodríguez, A. H. (2025) · Journal of Fungi · doi:10.3390/jof11050362 · Cited by 11
A machine learning model for early candidemia prediction in the intensive care unit: Clinical application
Meng, Q., Chen, B., Xu, Y., Zhang, Q., Ding, R., Gao, Q., Du, K., Ma, Z., Jin, Z., Gao, S., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0309748 · Cited by 12
Model-Optimized Fluconazole Dose Selection for Critically Ill Patients Improves Early Pharmacodynamic Target Attainment without the Need for Therapeutic Drug Monitoring
Sandaradura, I., Wojciechowski, J., Marriott, D. J. E., Day, R. O., STOCKER, S. L., & Reuter, S. E. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02019-20 · Cited by 10
De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemicCandidainfections
Masterton, R. G., Casamayor, M., Musingarimi, P., van Engen, A., Zinck, R., Odufowora-Sita, O., & Odeyemi, I. A. O. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2013.839948 · Cited by 10
When and How to Cover for Fungal Infections in Patients with Severe Sepsis and Septic Shock
Allou, N., Allyn, J., & Montravers, P. (2011) · Current Infectious Disease Reports · doi:10.1007/s11908-011-0204-x · Cited by 9
Early-Onset Candidemia in Adult Intensive Care Units
Mouratidou, C., Tsakiri, K., Dourliou, V., Marneri, A. G., Stougianni, M., & Pavlidis, E. T. (2025) · Diagnostics · doi:10.3390/diagnostics15111402 · Cited by 9
Strategies to manage antifungal drug resistance
Tseng, H.-K., & Perfect, J. R. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.517195 · Cited by 8
Prevalence and risk factors for endogenous fungal endophthalmitis in adult patients with candidemia at a tertiary care hospital in the Republic of Korea over 13 years
Kim, J. H., Suh, J. W., Kim, J. Y., Kim, S. B., Yoon, Y. K., Sohn, J. W., & Kim, M. J. (2020) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2020.101102 · Cited by 7
Clinical Syndromes: Candida and Candidosis
Ruhnke, M. (2018) · Springer eBooks · doi:10.1007/978-3-319-92300-0_4 · Cited by 7
Evaluation of Systemic Antifungal Prescribing Knowledge and Practice in the Critical Care Setting among ICU Physicians and Clinical Pharmacists: A Cross-Sectional Study
Ibrahim, S. M., Adlan, N., Alomair, S. M., Butaiban, I., Alsalman, A., Bawazeer, A., Alqahtani, M., Mohamed, D., & Emeka, P. M. (2023) · Antibiotics · doi:10.3390/antibiotics12020238 · Cited by 7
Complications of invasive mycoses in organ transplant recipients
Samanta, P., & Singh, N. (2016) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2016.1242412 · Cited by 7
Time-Lapse Tracking of Candida tropicalis Biofilm Formation and the Antifungal Efficacy of Liposomal Amphotericin B
Kawai, A., Yamagishi, Y., & Mikamo, H. (2017) · Japanese Journal of Infectious Diseases · doi:10.7883/yoken.jjid.2016.574 · Cited by 7
Multilaboratory Testing of Antifungal Drug Combinations against Candida Species and Aspergillus fumigatus: Utility of 100 Percent Inhibition as the Endpoint
Ren, P., Luo, M., Lin, S., Ghannoum, M. A., Isham, N. C., Diekema, D. J., Pfaller, M. A., Messer, S. A., Lockhart, S. R., Iqbal, N. J., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04545-14 · Cited by 7
Cost-effectiveness of de-escalation from micafungin versus escalation from fluconazole for invasive candidiasis in China
Chen, D., Wan, X., Kruger, E., Chen, C., Yue, X., Wang, L., & Wu, J. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2017.1417312 · Cited by 7
Clinical factors affecting costs in patients receiving systemic antifungal therapy in intensive care units in Greece: Results from the ESTIMATOR study
Armaganidis, A., Nanas, S., Antoniadou, E., Mandragos, K. E., Liakou, K., Koutsoukou, A., Baltopoulos, G. J., Nakos, G., Kounougeri, A., Ganas, K., et al. (2017) · Mycoses · doi:10.1111/myc.12616 · Cited by 6
"De-escalation" strategy using micafungin for the treatment of systemic Candida infections: budget impact in France and Germany
van Engen, A., Casamayor, M., Kim, S., Watt, M., & Odeyemi, I. A. O. (2017) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s141548 · Cited by 6
Appropriateness of antifungal prescribing in Oman
El-Hussain, F. I., Balkhair, A., Al-Zakwani, I., & Za’abi, M. A. (2022) · Pharmacy Practice · doi:10.18549/pharmpract.2022.1.2613 · Cited by 6
Pharmacoeconomics of antifungal therapy: current considerations
Ashley, E. D. (2011) · Current Opinion in Infectious Diseases · doi:10.1097/01.qco.0000399604.68268.79 · Cited by 5
Measuring the effect of inappropriate initial antibiotic therapy on outcomes of patients with Gram-negative sepsis: An imprecise science*
Sexton, D. J., Miller, B. A., & Anderson, D. J. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e318202e68f · Cited by 5
Evolution in the Management of Invasive Fungal Infections in Liver Transplant Recipients
Verma, A., Weigel, K., Dexter, S. Y. K., & Dhawan, A. K. (2018) · OBM Transplantation · doi:10.21926/obm.transplant.1802009 · Cited by 3
Assessment of Caspofungin use at a Tertiary Teaching Hospital and compliance with IDSA guidelines and FDA labelings
Alshehri, A. F., Almangour, T. A., Alhifany, A. A., & Alhossan, A. (2022) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2021.12.005 · Cited by 3
Diagnosis and Management of Invasive Candida Infections in Critically Ill Patients
Zakhem, A. E., Istambouli, R., Jabbour, J.-F., Hindy, J.-R., Gharamti, A. A., & Kanj, S. S. (2022) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0041-1741009 · Cited by 3
Clinical Experience of Anidulafungin for the Treatment of Patients with Documented Candidemia
Falcone, M., Russo, A., Rosa, F. G. D., Pasero, D., Toma, L., Raponi, G., Ghezzi, M. C., & Venditti, M. (2010) · Journal of Chemotherapy · doi:10.1179/joc.2010.22.6.397 · Cited by 3
Evaluation of semi-nested polymerase chain reaction (PCR) and mannan antigen detection compared to blood culture for diagnosis of candidemia
Nashwa, M. A.-K., Nermein, A. E. K., Mohammed, M., & Zaki, M. E. S. (2017) · African Journal of Microbiology Research · doi:10.5897/ajmr2017.8613 · Cited by 3
A Case–Control Study of Candidaemia in Very Low Birthweight Infants in a Tertiary Hospital in Johannesburg
Malunga, C., Nana, T., & Ballot, D. E. (2020) · Wits Journal of Clinical Medicine · doi:10.18772/26180197.2020.v2n1a4 · Cited by 3
Azoles: back to the future
Perfect, J. R. (2011) · Current Opinion in Infectious Diseases · doi:10.1097/01.qco.0000399605.75891.fc · Cited by 3
Augmented Renal Clearance
Shorr, A. F., & Zilberberg, M. D. (2014) · Critical Care Medicine · doi:10.1097/ccm.0000000000000081 · Cited by 3
Self-citation
An innovative fungal-specific targeted next-generation sequencing method: analytical performance and a single-center prospective clinical study
Wang, R., Cheng, S., Du, W., Sun, F., Gao, Y., Zhu, Z., He, C., Chen, J., Tian, S., Chu, Y., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06784-w · Cited by 4

Authors: Zilberberg, M. D., Kollef, M. H., Arnold, H., Labelle, A., Micek, S. T., Kothari, S., & Shorr, A. F.
Affiliations: Washington University in St. Louis (US)
Astellas Pharma (United States) (US)
MedStar Washington Hospital Center (US)
Corresponding author: Zilberberg, Marya D
ORCID: Zilberberg, Marya D
Kollef, Marin H
Kothari, Smita
Shorr, Andrew F
Venue: BMC Infectious Diseases
Publisher: Springer Science and Business Media LLC
Published: 2010-06-03
Volume: 10
Issue: 1
Pages: 150-150
ISSN: 1471-2334 (ISSN-L)
DOI: 10.1186/1471-2334-10-150
PMC: PMC2890008
OpenAlex: W2129412480
Cited by: 128
References: 19
Citations by year: 2026: 1 · 2025: 8 · 2024: 4 · 2023: 2 · 2022: 5 · 2021: 8 · 2020: 10 · 2019: 5 · 2018: 7 · 2017: 9 · 2016: 7 · 2015: 9 · 2014: 15 · 2013: 7 · 2012: 11
FWCI: 7.88
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/2.0 (tdm)
Locations: BMC Infectious Diseases (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics: Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
Keywords: candidemia, antifungal dosing, length of hospital stay, hospital costs, hospital resource utilization, intensive care unit, invasive fungal infections, mortality
MeSH terms: Adult, Aged, Antifungal Agents, Candidiasis, Female, Health Services Research, Hospitals, Humans, Intensive Care Units, Length of Stay, Male, Middle Aged, Retrospective Studies, Cohort Studies, Fungemia, Treatment Outcome, Health Care Costs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks